We are live on ! Find out more
GPCM

Granite Point Capital Management Portfolio holdings

AUM $4.9M
1-Year Est. Return 38.41%
This Fund
S&P 500
This Quarter Est. Return
+2.1%
1 Year Est. Return
+38.41%
3 Year Est. Return
+124.67%
5 Year Est. Return
+295.96%
10 Year Est. Return
–
AUM
$125M
AUM Growth
-$131M
Cap. Flow
-$755K
Cap. Flow %
-0.6%
Top 10 Hldgs %
39.36%
Holding
112
New
21
Increased
21
Reduced
8
Closed
32

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.61M
2
AXGN icon
Axogen
AXGN
+$2.46M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$2.42M
4
BAC icon
Bank of America
BAC
+$2.41M
5
HDSN
Hudson Technologies
HDSN
+$1.84M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$4.91M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$4.02M
3
HIMX
Himax Technologies
HIMX
+$3.25M
4
CY
Cypress Semiconductor
CY
+$2.13M
5
MEET
The Meet Group, Inc. Common Stock
MEET
+$1.81M

Sector Composition

Rank Sector Weight
1 Healthcare 34.83%
2 Technology 14.08%
3 Consumer Discretionary 12.52%
4 Miscellaneous 10.65%
5 Communication Services 9.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$474B
$8.29M 6.61%
70,000
-105,500
-60% -$12.4M
ARIA
2
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$5.8M 4.62%
466,015
+8,600
+2% +$104K
SHAK icon
3
Shake Shack
SHAK
$2.37B
$5.37M 4.28%
150,001
– –
AERI
4
DELISTED
Aerie Pharmaceuticals
AERI
$5.09M 4.06%
134,500
– –
META icon
5
Meta Platforms (Facebook)
META
$1.71T
$4.88M 3.89%
42,400
– –
ADMS
6
DELISTED
Adamas Pharmaceuticals
ADMS
$4.33M 3.45%
256,031
+31,700
+14% +$490K
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$32.1B
$4.12M 3.28%
+110,000
New +$4.61M
JPM icon
8
JPMorgan Chase
JPM
$940B
$4.06M 3.23%
47,000
+10,625
+29% +$810K
AMZN icon
9
Amazon
AMZN
$2.67T
$3.81M 3.03%
101,500
– –
NVRO
10
DELISTED
NEVRO CORP.
NVRO
$3.63M 2.9%
50,000
+2,200
+5% +$188K
ACRS icon
11
Aclaris Therapeutics
ACRS
$810M
$3.56M 2.83%
131,000
+95,000
+264% +$2.42M
TK icon
12
Teekay
TK
$1.25B
$3.28M 2.61%
408,275
– –
AXGN icon
13
Axogen
AXGN
$2.43B
$3.17M 2.53%
352,000
+285,000
+425% +$2.46M
HIMX
14
CALL
Himax Technologies
HIMX
$2.28B
$3.08M 2.46%
550,000
– –
BAC icon
15
Bank of America
BAC
$417B
$2.76M 2.2%
+125,000
New +$2.41M
NTES icon
16
NetEase
NTES
$76.5B
$2.75M 2.19%
63,875
+7,500
+13% +$358K
HDSN
17
Hudson Technologies
HDSN
$218M
$2.68M 2.14%
335,000
+260,000
+347% +$1.84M
MB
18
DELISTED
MINDBODY, Inc. Class A Common Stock
MB
$2.57M 2.05%
120,698
– –
NVDA icon
19
NVIDIA
NVDA
$5.12T
$1.92M 1.53%
720,000
– –
BFYT
20
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
$1.78M 1.42%
+100,000
New +$976K
SOHU
21
Sohu.com
SOHU
$356M
$1.74M 1.39%
51,300
+46,300
+926% +$1.73M
SIMO icon
22
Silicon Motion
SIMO
$8.04B
$1.7M 1.35%
+40,000
New +$1.83M
EVBG
23
DELISTED
Everbridge, Inc. Common Stock
EVBG
$1.69M 1.35%
91,500
– –
SRPT icon
24
Sarepta Therapeutics
SRPT
$2.2B
$1.65M 1.31%
60,000
-100,000
-63% -$4.02M
AEIS icon
25
Advanced Energy
AEIS
$9.93B
$1.64M 1.31%
+30,000
New +$1.54M
1
2 3 4 5

Similar funds

MAM
Moelis Asset Management New York $5.32M AUM
CCM
Compton Capital Management Providence, Rhode Island $4.32M AUM 27.38% 1-Year Est. Return
BGCI
Bertram Growth Capital III Foster City, California $6.05M AUM 39.41% 1-Year Est. Return
CAM
Chatham Asset Management Chatham, New Jersey $376K AUM
EAM
Emso Asset Management London, United Kingdom $255K AUM 6.95% 1-Year Est. Return
SM
SG3 Management Dorado, Puerto Rico $6.45K AUM 61.81% 1-Year Est. Return
TPL
Tao Pro LLC San Francisco, California $13.8M AUM 74.14% 1-Year Est. Return
RC
Resonate Capital San Francisco, California $15.4M AUM 24.26% 1-Year Est. Return

Granite Point Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Granite Point Capital Management held 112 positions worth $125M, down 51% from $256M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Granite Point Capital Management's Q4 2016 filing shows 21 new, 21 increased, 8 reduced and 32 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 110,000 shares worth $4.12M. The largest sale was Apple, an estimated $4.91M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 20% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Granite Point Capital Management's largest Q4 2016 buy was Alnylam Pharmaceuticals: 110,000 shares worth $4.12M.
  • Granite Point Capital Management added most to Axogen in Q4 2016, an estimated $2.46M increase.
  • Granite Point Capital Management's biggest Q4 2016 reduction was Sarepta Therapeutics, cutting an estimated $4.02M.
  • Granite Point Capital Management fully exited Apple in Q4 2016, selling an estimated $4.91M.
  • Granite Point Capital Management's ten largest holdings make up 39% of its $125M portfolio in Q4 2016.
  • Granite Point Capital Management opened 21 new positions and closed 32 in Q4 2016.
  • Granite Point Capital Management's portfolio value fell 51% quarter-over-quarter to $125M.

Based on Granite Point Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.